Furthermore, given the fact that ibrutinib-based therapy did not directly increase LOH of the wild-type Trp53 allele in treated Eμ-TCL1;p53R172H/+ leukemias compared with untreated Eμ-TCL1;p53R172H/+ leukemias, these data also imply that the p53 pathway will remain partially active in these patients. Here, TP53 is linked to leukemia.